Drug class in one race
HER3 drugs for Non-Small Cell Lung Cancer
6 tracked HER3 drugs in the Non-Small Cell Lung Cancer race. The class explanation lives on the HER3 page; the full indication pipeline across every mechanism is on the Non-Small Cell Lung Cancer page.
2 Phase 33 Phase 1/21 preclinical / unstaged
Head-to-head evidence: AK138D1 vs Patritumab Deruxtecan · DB-1310 vs Patritumab Deruxtecan · ENV-501 vs Patritumab Deruxtecan · HMBD-001 vs Patritumab Deruxtecan · Patritumab Deruxtecan vs SHR-A2009